Type 2 diabetes

Jan 24, 2023

BeiGene’s Brukinsa Approval; FDA Approval to Seagen’s TUKYSA; NICE Recommends Alnylam’s Amvuttra; FDA Approves Brenzavvy for Type 2 Diabetes; Roche’s Tecentriq to be Filed for Early-stage Liver Cancer; FDA Lifts Hold on Astellas’ Pompe Gene Therapy

Jan 17, 2023

FDA Approves Luye’s Rykindo; EU Approves AstraZeneca’s Tezspire; Oramed Announces Trial Results of ORMD-0801; Eisai and Biogen File Lecanemab in the EU; AbbVie and Anima Biotech Announce Collaboration; AstraZeneca’s Avillion Receives FDA Approval

May 17, 2022

BMS Sells NY Biologics Plant; FDA Approves Mitsubishi Tanabe’s Radicava, Love Pharma Acquires MicroDoz; Sandoz Launches Generic of Roche’s Esbriet; Pfizer to Acquire Biohaven Pharma; eureKARE’s Cell and Gene Therapy CDMO; Atamyo’s LGMD Gene Therapies; FDA approves Eli Lilly’s Type 2 Diabetes Treatment

Mar 30, 2022

Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022

Mar 16, 2022

Can Cannabinoids be an Effective Medicinal Substance?

Feb 22, 2022

Sandoz’s Generic Revlimid; Agios’ Pyrukynd; Organon Announces 4Q & Full-year Earnings Report; BMS’ CAR-T Drug Breyanzi; Sanofi & Regeneron’s Dupixent Trial; AZ & Daiichi’s Drug Enhertu; Bayer’s Drug Kerendia; Lilly Releases Mirikizumab Data

Apr 28, 2021

Understanding The Increasing Prevalence Of Diabetes And Its Complications

Jun 17, 2020

The Question That Remains Unanswered: What Might Be Causing Alzheimer’s?

May 26, 2020

Algernon’s NP-120; FDA nod to 4DMedical tool; SaNOtize’s NORSTM trial; Pole’s capital increase

Jan 23, 2020

Tepezza receives approval; a new way to treat Alzheimer’s

Newsletter/Whitepaper